OSN New York and OSN New York Retina
OSN New York and OSN New York Retina
Source/Disclosures
Source:

Van Tassel S. Depot drug delivery for glaucoma. Presented at: OSN New York and OSN New York Retina; Oct. 17-18, 2020 (virtual meeting).

Disclosures: Van Tassel reports financial disclosures for Aerie, Allergan, Bausch + Lomb and Equinox.
October 20, 2020
1 min read
Save

Sustained-release glaucoma medications needed to reduce treatment burden

Source/Disclosures
Source:

Van Tassel S. Depot drug delivery for glaucoma. Presented at: OSN New York and OSN New York Retina; Oct. 17-18, 2020 (virtual meeting).

Disclosures: Van Tassel reports financial disclosures for Aerie, Allergan, Bausch + Lomb and Equinox.
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Between poor patient adherence and the inherent IOP peaks and troughs associated with eye drop-managed glaucoma, sustained-release medications are greatly needed, a presenter at the virtual OSN New York meeting said.

About half of all patients taking eye drops struggle with adherence, especially with midday doses, and about two-thirds do not administer the drops correctly, Sarah H. Van Tassel, MD, said.

Furthermore, laser and surgical therapies are not appropriate for all patients because of prior glaucoma surgery, angle anatomy not amenable to selective laser trabeculoplasty, patient resistance and medical comorbidities, she said.

Sarah H. Van Tassel, MD
Sarah H. Van Tassel

“This context demonstrates that there is a great need for sustained-release glaucoma medications,” Van Tassel said.

In March, the FDA approved Durysta (bimatoprost sustained-release intracameral implant, Allergan) for IOP reduction in patients with open-angle glaucoma or ocular hypertension. Efficacy was demonstrated in two phase 3 studies that showed IOP reduction of approximately 5 mm Hg to 8 mm Hg in patients with mean IOP of 24.5 mm Hg at baseline. The most common ocular adverse event was conjunctival hyperemia in about 27% of patients, Van Tassel said.

Van Tassel identifies patients who may be suitable for such sustained delivery of medication as those who have challenges administering their eye drops, such as those with arthritis or forgetfulness, and those who react to benzalkonium chloride.

“In our practice lifetimes, we will surely see additional sustained-release medication options,” Van Tassel said, including punctal plugs, ring-type systems, contact lenses, implants, microspheres, nanospheres and gels.

Determinants of their success include efficacy, duration, safety, cost/reimbursement, patient acceptance and ease of office flow.